Cogent Biosciences (COGT) CEO Robbins gifts 320,000 shares in estate move
Cogent Biosciences CEO Andrew Robbins reported two bona fide gifts totaling 320,000 company shares on May 19, 2026. These gifts, made for estate planning purposes, included 160,000 shares transferred to a family trust and another 160,000 shares gifted from his direct holdings, both at a price of $0.00 per share. Following these transactions, Robbins' direct ownership is 497,503 common shares, with the family trust holding an additional 160,000 shares indirectly.
A Look At Cogent Biosciences (COGT) Valuation After New APEX And JAK2 Data Presentations Are Announced
Cogent Biosciences (COGT) has gained attention due to upcoming presentations of APEX trial data for bezuclastinib and new JAK2 data. Despite significant multi-year returns and an analyst price target above its current value, the stock has experienced a recent short-term dip. The company's valuation, reflected by its 10.8x Price-to-Book ratio, is considered high given its current unprofitability and lack of meaningful revenue, heavily relying on future pipeline success.
A Look At Cogent Biosciences (COGT) Valuation After New APEX And JAK2 Data Presentations Are Announced
Cogent Biosciences' (COGT) valuation is under review following new APEX and JAK2 data presentations, despite a significant multi-year shareholder return. The company's Price to Book (P/B) ratio of 10.8x is considerably higher than industry averages, reflecting investor confidence in its clinical pipeline rather than current unprofitable financials. While the upcoming data presentation could be a catalyst, the high P/B suggests that the valuation is largely speculative and sensitive to trial outcomes and market sentiment.
A Look At Cogent Biosciences (COGT) Valuation After New APEX And JAK2 Data Presentations Are Announced
Cogent Biosciences (COGT) has gained attention after announcing upcoming APEX trial data for bezuclastinib at the European Hematology Association 2026 Congress. Despite a significant multi-year shareholder return, the stock has seen a recent pullback. The article questions whether Cogent is undervalued, noting its high Price-to-Book ratio of 10.8x compared to industry averages and its current unprofitability, suggesting its valuation heavily relies on future clinical pipeline success.
Cogent Biosciences (NASDAQ: COGT) group reports 9,043,903 shares
A Schedule 13G/A filing reveals that Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn collectively beneficially own 9,043,903 shares of Cogent Biosciences (NASDAQ: COGT) common stock. This represents 5.29% of the class as of March 31, 2026. The filing indicates shared voting and dispositive power attributed to Deerfield Partners, L.P.
COGT SEC Filings - Cogent Biosciences Inc 10-K, 10-Q, 8-K Forms
This page provides access to Cogent Biosciences Inc (COGT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, and 8-K current reports. It details the company's focus on precision therapies and notes recent filings cover financial results, business updates, clinical data, and corporate governance matters. StockTitan tracks 43 COGT filings, with the most recent being on July 8, 2025.
Cogent Biosciences Announces Presentations of Pivotal APEX Trial Data and JAK2 V617F Program at EHA Congress 2026
Cogent Biosciences announced that data from its pivotal APEX trial for bepranemab in patients with advanced systemic mastocytosis will be presented at the EHA Congress 2026. The company will also provide an update on its selective JAK2 V617F inhibitor program, CGT2428, aimed at treating myeloproliferative neoplasms. These presentations highlight Cogent's advancements in oncology and rare disease drug development.
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
Cogent Biosciences will present pivotal data from its APEX trial in Advanced Systemic Mastocytosis and preclinical data from its JAK2 V617F program at the European Hematology Association (EHA) 2026 Congress. The APEX trial results for bezuclastinib in Advanced Systemic Mastocytosis will be featured in an oral presentation, marking the company's third oral presentation of pivotal data for this drug. Additionally, a poster will detail preclinical findings for a novel, selective JAK2 V617F mutant-selective inhibitor.
Advanced mastocytosis trial data and JAK2 inhibitor at EHA 2026
Cogent Biosciences will present new data at the European Hematology Association (EHA) 2026 Congress, including a pivotal oral presentation on the APEX trial for Advanced Systemic Mastocytosis and preclinical data for its JAK2 V617F inhibitor program. This announcement follows several recent positive milestones for the company, such as FDA acceptance of bezuclastinib NDAs and strong Phase 3 GIST data, indicating continued clinical and scientific progress. Investors will be looking for detailed efficacy and safety readouts from the APEX trial and further advancements in its pipeline.
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
Cogent Biosciences announced its Q1 2026 financial results and provided a business update, highlighting its plans for dual launches of bezuclastinib in Systemic Mastocytosis and GIST. The company reported $866.4 million in cash, expected to fund operations into 2028, and detailed several key milestones including NDA submissions and clinical trial presentations.
Pier Capital LLC Buys Shares of 46,260 Cogent Biosciences, Inc. $COGT
Pier Capital LLC acquired a new stake of 46,260 shares in Cogent Biosciences (NASDAQ:COGT), valued at approximately $1.64 million, during the fourth quarter. Other institutional investors like Vanguard, Deerfield, Fairmount, and Commodore significantly increased their holdings. Cogent Biosciences, a clinical-stage biopharmaceutical company, shows mixed but leaning positive analyst coverage with a "Moderate Buy" consensus and an average price target of $43.73, despite operating at a pre-profit stage with projected negative EPS for the current year.
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), OnKure Therapeutics (OKUR) and Cogent Biosciences (COGT)
BMO Capital maintained a Hold rating on Novo Nordisk (NVO) with a $36.00 price target. JonesTrading issued a Hold rating on OnKure Therapeutics (OKUR), while LifeSci Capital maintained a Buy rating on Cogent Biosciences (COGT) with a $55.00 price target. The article highlights analyst consensus ratings and average price targets for each company, indicating potential upside or downside from current levels.
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
Cogent Biosciences announced its first-quarter 2026 financial results and provided a business update, highlighting its progress with bezuclastinib. The company is preparing for dual launches of bezuclastinib for Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST), with pivotal data for GIST to be presented at the 2026 ASCO meeting. Cogent ended the quarter with $866.4 million in cash, expected to fund operations into 2028.
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
Cogent Biosciences provided a business update and announced first quarter 2026 financial results, highlighting plans for dual launches of bezuclastinib for Systemic Mastocytosis and GIST, with pivotal data from the Phase 3 PEAK trial selected for an oral presentation at the ASCO annual meeting. The company ended Q1 2026 with $866.4 million in cash, sufficient to fund operations into 2028, and is preparing for multiple anticipated drug launches. Key upcoming milestones include additional NDA submissions and the initiation of new clinical trials for their pipeline candidates.
Biotechnology company Cogent Biosciences, Inc.'s latest financial data shows that as of the end of the first quarter of 2026, the company held a total of $866.4 million in cash and cash equivalents.
As of the end of Q1 2026, Cogent Biosciences, Inc. reported $866.4 million in cash and cash equivalents, which is projected to sustain operations until at least 2028. This substantial capital base is expected to support the company's research, development, and commercialization efforts, particularly for its core drug candidate BEZ-235. Management plans to continue a prudent capital allocation strategy, focusing on oncology targeted therapy development.
BRIEF-Cogent Biosciences Q1 Income From Operations USD -103.607 Million
Cogent Biosciences reported a Q1 income from operations of USD -103.607 million. This brief financial update is provided by Refinitiv and concerns the company with ticker symbol COGT.
Bezuclastinib NDAs and cash into 2028 at Cogent Biosciences (NASDAQ: COGT)
Cogent Biosciences reported a Q1 2026 net loss of $97.4 million, with total operating expenses of $103.6 million, due to increased R&D and G&A spending as it prepares for potential product launches. The company ended the quarter with $866.4 million in cash, cash equivalents, and marketable securities, which it expects will fund operations into 2028. Cogent has multiple New Drug Applications (NDAs) for bezuclastinib under FDA review, including for systemic mastocytosis and GIST, with a PDUFA target action date of December 30, 2026, for non-advanced systemic mastocytosis.
Biotechnology company Cogent Biosciences, Inc.'s latest financial data shows that as of the end of the first quarter of 2026, the company held a total of $866.4 million in cash and cash equivalents.
Biotechnology company Cogent Biosciences, Inc. reported $866.4 million in cash and cash equivalents at the end of the first quarter of 2026, providing financial stability for research, development, and commercialization activities until at least 2028. This substantial reserve supports the clinical advancement of its core drug candidate, BEZ-235, and reflects strong investor confidence. The company plans to continue a prudent capital allocation strategy, focusing on promising oncology targeted therapies.
Cogent Biosciences 1Q 2026: Net loss $(97.4)M, EPS $(0.53) — 10-Q Summary
Cogent Biosciences reported a consolidated net loss of $(97.4) million, or diluted EPS of $(0.53) for the first quarter of 2026, marking an increase in net loss compared to the previous year. The company highlighted significant business advancements including positive registrational results for bezuclastinib, regulatory progress for its NDA filings with a planned launch in H2 2026, and pipeline expansion with new Phase 1 studies. Cogent Biosciences also estimates a combined market potential of over $8 billion for GIST and systemic mastocytosis.
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
Cogent Biosciences announced its first quarter 2026 financial results, highlighting progress in its precision therapies. The company is preparing for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) in the second half of 2026, with pivotal data from the Phase 3 PEAK trial to be presented at ASCO. Cogent reported $866.4 million in cash, sufficient to fund operations into 2028.
Cogent Biosciences (COGT) boosts cash to fund bezuclastinib NDAs and launch plans
Cogent Biosciences reported a wider net loss of $97.4 million for Q1 2026 but strengthened its cash position to $866.4 million, extending its cash runway into 2028. This funding will support the commercialization of bezuclastinib, with New Drug Applications submitted for systemic mastocytosis and GIST, and ongoing development for other targeted therapies. The company is transitioning from an R&D focus to late-stage development and commercialization, backed by positive clinical trial results and recent financing activities.
Biotechnology company Cogent Biosciences, Inc.'s latest financial data shows that as of the end of the first quarter of 2026, the company held a total of $866.4 million in cash and cash equivalents.
Cogent Biosciences, Inc. reported $866.4 million in cash and cash equivalents at the end of the first quarter of 2026, which is expected to fund operations and R&D until at least 2028. This substantial cash reserve, significantly higher than the industry average, supports the clinical advancement of its core drug candidate BEZ-235. Management plans a prudent capital allocation strategy, focusing on promising oncology targeted therapy development.
Pictet Asset Management Holding SA Boosts Holdings in Cogent Biosciences, Inc. $COGT
Pictet Asset Management Holding SA significantly increased its stake in Cogent Biosciences, Inc. (NASDAQ:COGT) by 710.7% in Q4 2025, now holding 112,476 shares valued at $4.23 million. Other institutional investors also adjusted their positions in the company. Cogent Biosciences, a clinical-stage biopharmaceutical company, opened at $36.63, has a market cap of $6.26 billion, and analyst sentiment is currently "Moderate Buy" with an average target price of $43.45.
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Analysts
Cogent Biosciences (NASDAQ:COGT) has received an average "Moderate Buy" rating from fourteen analysts, with a 1-year average price target of $43.45. While several firms have raised their price targets up to $55, some maintain "sell" ratings. The clinical-stage biopharma company, focused on developing therapies for solid tumors, reported a quarterly EPS loss of ($0.55), missing estimates.
Teachers Retirement System of The State of Kentucky Invests $1.33 Million in Cogent Biosciences, Inc. $COGT
The Teachers Retirement System of the State of Kentucky initiated a new position in Cogent Biosciences (NASDAQ:COGT), acquiring 37,445 shares valued at approximately $1.33 million in Q4. This move is part of broader institutional interest, with other major investors like Fairmount Funds and Vanguard also increasing their stakes. Despite a recent earnings miss, analysts generally hold a bullish outlook for Cogent Biosciences, setting an average price target of $43.45.
Cogent Biosciences, Inc. (NASDAQ:COGT) Sees Large Drop in Short Interest
Cogent Biosciences (NASDAQ:COGT) experienced a significant 30.9% drop in short interest in April, totaling 12,038,491 shares. The company maintains a "Moderate Buy" consensus rating from analysts with an average price target of $43.45. Trading near $36.56, Cogent Biosciences has a market capitalization of $6.24 billion and recently reported a quarterly loss of ($0.55) EPS.
Cogent Biosciences (COGT) Expected to Announce Quarterly Earnings on Tuesday
Cogent Biosciences (COGT) is projected to report its Q1 2026 earnings before the market opens on Tuesday, May 5th, with analysts forecasting a loss of ($0.53) per share. The company, a clinical-stage biopharmaceutical firm, will hold its earnings call on May 6th, and has an average "Moderate Buy" rating from analysts with an average price target of $43.45. Its stock price recently saw a slight increase, trading at $36.79, and shows significant institutional interest with several firms newly acquiring stakes.
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM
Cogent Biosciences (COGT) shares rose after the FDA accepted its New Drug Application (NDA) for bezuclastinib to treat non-advanced systemic mastocytosis (SM). The FDA granted Priority Review, setting a PDUFA date for February 28, 2027. This acceptance marks a significant step for Cogent in bringing a new treatment option to patients with this rare disease.
A Look At Cogent Biosciences (COGT) Valuation After New KRAS And ErbB2 Data At AACR 2026
Cogent Biosciences (COGT) presented new preclinical data for its KRAS and ErbB2 candidates at AACR 2026, showcasing positive selectivity, activity, and safety. The stock is trading at $36.81, below the average analyst target of $54.17. The article explores whether the company's Price-to-Book ratio of 10.8x is justified, noting it appears expensive compared to broad biotech peers but discounted within its closer peer group, while also highlighting risks such as trial disappointments and funding needs.
A Look At Cogent Biosciences (COGT) Valuation After New KRAS And ErbB2 Data At AACR 2026
Cogent Biosciences (COGT) is under scrutiny following new preclinical data for its KRAS and ErbB2 drug candidates presented at AACR 2026. The company's stock, currently at $36.81, trades at a significant discount to the average analyst target of $54.17. While its price-to-book ratio of 10.8x appears high compared to the wider biotech industry, it is a considerable discount when set against closer peers, indicating a potentially mispriced oncology story that necessitates further investor review.
[ARS] Cogent Biosciences, Inc. SEC Filing
This article announces an ARS SEC Filing by Cogent Biosciences, Inc. (COGT) on April 23, 2026. The filing has a low impact and neutral sentiment. It also provides an overview of COGT's stock data, recent news, and other SEC filings.
Cogent Biosciences (NASDAQ: COGT) details 2026 proxy, pivotal bezuclastinib wins and $901M cash
Cogent Biosciences (NASDAQ: COGT) has filed its 2026 proxy statement, highlighting significant achievements in 2025 including positive results from three registrational trials for its drug bezuclastinib in Systemic Mastocytosis (SM) and Gastrointestinal Stromal Tumors (GIST). The company also strengthened its financial position with $901 million in cash, cash equivalents, and marketable securities, projected to fund operations into 2028. Stockholders will vote on director elections, auditor ratification, and executive compensation at the virtual annual meeting on June 9, 2026.
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors at the 2026 American Society of Clinical Oncology Annual Meeting
Cogent Biosciences announced that positive results from its Phase 3 PEAK trial for bezuclastinib in combination with sunitinib for Gastrointestinal Stromal Tumors (GIST) will be presented at the 2026 ASCO Annual Meeting. The trial evaluated patients who had prior treatment with imatinib, with top-line results reported in November 2025 and an NDA submitted in March 2026. The company also plans to initiate a Phase 2 trial for first-line GIST patients with exon 9 mutations.
Cogent’s positive tumor trial lands an oral presentation at ASCO
Cogent Biosciences announced that its positive Phase 3 PEAK trial results for bezuclastinib plus sunitinib in gastrointestinal stromal tumors (GIST) will be presented orally at the 2026 ASCO Annual Meeting. The company had previously reported top-line results in November 2025 and submitted a New Drug Application (NDA) under the Real-Time Oncology Review (RTOR) program in March 2026. Cogent also plans to initiate a Phase 2 trial this quarter for first-line exon 9 GIST patients.
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research Annual Meeting 2026
Cogent Biosciences announced that it will present preclinical data from its KRAS and ErbB2 pipeline programs at the American Association for Cancer Research (AACR) Annual Meeting 2026. The presentations will feature CGT1263, a novel pan-KRAS(ON) inhibitor with potential to reduce skin toxicity, and CGT4255, a brain-penetrant ErbB2 inhibitor showing synergistic activity with HER2 ADCs. These data highlight the company's focus on developing precision therapies for genetically defined diseases and advancing multiple potential blockbuster programs.
Analysts Expect Breakeven For Cogent Biosciences, Inc. (NASDAQ:COGT) Before Long
Analysts are forecasting that Cogent Biosciences, Inc. (NASDAQ:COGT) will reach breakeven profitability in the near future, specifically by 2025. The company recently reported a smaller-than-expected Q4 2023 loss per share and has seen a substantial increase in its share price over the past year. While some analysts have revised their outlooks, the consensus remains positive regarding the company's path to profitability.
Is AACR 2026 KRAS and ErbB2 Data Altering The Investment Case For Cogent Biosciences (COGT)?
Cogent Biosciences recently presented promising preclinical data for its KRAS(ON) inhibitor CGT1263 and brain-penetrant ErbB2 inhibitor CGT4255 at the AACR Annual Meeting 2026. While these early-stage programs add depth to Cogent's long-term pipeline, the company's investment case primarily remains dependent on the approval and commercialization of bezuclastinib, with a PDUFA date in late 2026 being a key near-term catalyst. The new data enhances the overall narrative by demonstrating optionality in key cancer pathways, but investors should be aware of the significant reliance on bezuclastinib's success given the company's current financial situation.
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
Cogent Biosciences announced upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026, showcasing preclinical data from their KRAS and ErbB2 pipeline programs. The presentations will include updated findings on CGT1263, a pan-KRAS(ON) inhibitor designed to reduce skin toxicity, and CGT4255, a brain-penetrant ErbB2 inhibitor showing synergistic activity with HER2 ADCs. These updates highlight the company's progress in developing precision therapies for genetically defined diseases.
Cogent spotlights a safer KRAS drug and a brain-targeting HER2 therapy
Cogent Biosciences announced new preclinical data for two of its pipeline programs, CGT1263 (pan-KRAS(ON) inhibitor) and CGT4255 (EGFR-sparing ErbB2 inhibitor), at the AACR Annual Meeting 2026. CGT1263 demonstrated high selectivity for KRAS, suggesting reduced skin toxicity, with an IND submission expected later this year. CGT4255 showed strong CNS penetration potential and synergistic activity with HER2 ADCs, with a Phase 1 study currently underway.
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
Cogent Biosciences announced upcoming poster presentations at the AACR Annual Meeting 2026, showcasing preclinical data for two pipeline programs: CGT1263, a pan-KRAS(ON) inhibitor designed to reduce skin toxicity, and CGT4255, a brain-penetrant ErbB2 inhibitor. The company highlights CGT1263's selectivity advantage and CGT4255's potential synergistic activity with HER2 ADCs for resistant patients, underscoring the long-term potential of its pipeline.
Cogent Biosciences (COGT): Billionaire Stan Druckenmiller admires upside potential of this stock
The article states that billionaire investor Stan Druckenmiller sees upside potential in Cogent Biosciences (COGT) stock. It implies this is a significant endorsement given Druckenmiller's reputation.
Cogent Biosciences (COGT): Billionaire Stan Druckenmiller admires upside potential of this stock
This article highlights that billionaire investor Stan Druckenmiller sees significant upside potential in Cogent Biosciences (COGT) stock. The content, though brief, suggests an endorsement of COGT by a a prominent financial figure, which could indicate a positive outlook for the company's future performance.
COGT News | COGENT BIOSCIENCES INC (NASDAQ:COGT)
This article provides news and stock information for Cogent Biosciences Inc. (NASDAQ: COGT), including its current stock price and pre-market activity. It also lists various sections available on the ChartMill.com platform for analyzing the company, such as technical analysis, fundamental analysis, and earnings reports, along with a link to all press releases.
Cogent Biosciences (COGT) Is Up 6.1% After FDA NDA Filing For Bezuclastinib In GIST
Cogent Biosciences' stock rose by 6.1% following the submission of a New Drug Application (NDA) to the FDA for bezuclastinib to treat imatinib-treated GIST, supported by positive Phase 3 PEAK data. The drug is being reviewed under the Real-Time Oncology Review program with Breakthrough Therapy Designation, increasing expectations for regulatory approvals. While promising, the company remains pre-revenue and loss-making, making it sensitive to any regulatory or safety setbacks despite investor interest and expanded access programs.
Cogent Biosciences (COGT) Is Up 6.1% After FDA NDA Filing For Bezuclastinib In GIST
Cogent Biosciences has filed a New Drug Application (NDA) with the FDA for bezuclastinib to treat previously imatinib-treated GIST, supported by positive Phase 3 data and under review via the Real-Time Oncology Review program with Breakthrough Therapy Designation. The company's investment narrative heavily relies on the successful approval and commercialization of bezuclastinib across several indications, balanced against its pre-revenue status, cash burn, and rich valuation. Regulatory catalysts for NonAdvSM, AdvSM, and GIST are key to its future, with current shareholder risk tied to potential overvaluation and the concentrated bet on these NDA outcomes.
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Rating of "Moderate Buy" by Analysts
Cogent Biosciences (NASDAQ:COGT) has received an average "Moderate Buy" rating from fourteen brokerages, with an average 12-month price target of $43.45. Several analysts have recently raised their price targets, indicating bullish sentiment. Despite a major insider sale and missing quarterly EPS estimates, institutional investors have increased their holdings, and the company is developing small-molecule therapies for cancer.
A Look At Cogent Biosciences (COGT) Valuation After FDA Acceptance Of Bezuclastinib NDA
Cogent Biosciences (COGT) is under investor scrutiny following the FDA's acceptance of its New Drug Application for bezuclastinib in Gastrointestinal Stromal Tumors. Despite a recent share price decline, the company shows strong long-term shareholder returns. The article analyzes Cogent's valuation, noting its high Price-to-Book ratio compared to the industry average but a discount when measured against direct peers, suggesting a balanced risk-reward profile tied to future clinical outcomes.
A Look At Cogent Biosciences (COGT) Valuation After FDA Acceptance Of Bezuclastinib NDA
Cogent Biosciences is under investor scrutiny after the FDA accepted its New Drug Application for bezuclastinib, a drug reducing disease progression risk by 50% in Gastrointestinal Stromal Tumors. Valued at $5.7 billion with a P/B ratio of 10.4x, it's considered expensive compared to the broader biotech industry but discounted relative to its direct peers, despite significant net losses and minimal revenue. The company faces high risks due to its early stage, reliance on trial outcomes, and FDA decisions.
[Form 4] Cogent Biosciences, Inc. Insider Trading Activity
Cogent Biosciences director Karen Jean Ferrante received a stock option award for 686 shares, granted on April 1, 2026, with an exercise price of $35.24 and an expiration date of April 1, 2036. This award was compensation for her services as a non-employee director, where she opted for stock options instead of cash. Following this transaction, she directly holds options for 686 shares.
Guggenheim Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $45
Guggenheim has reiterated its Buy rating on Cogent Biosciences (COGT.US) and maintained a target price of $45. This suggests a continued positive outlook on the company's stock performance by the investment firm.
